• Ertugliflozin (PF-04971729): SGLT2 Inhibition for Diabetes R

  2026-06-21

  Ertugliflozin (PF-04971729) is a highly selective sodium-glucose co-transporter 2 (SGLT2) inhibitor used in diabetes mellitus research. It demonstrates over 2000-fold selectivity for SGLT2 versus SGLT1, robustly inhibits renal glucose reabsorption, and exhibits additional cardioprotective and anti-inflammatory effects supported by peer-reviewed studies.

• 2-NBDG Glucose Uptake Assay Kit: Precision in Metabolism Res

  2026-06-20

  The 2-NBDG Glucose Uptake Assay Kit enables rapid, non-radioactive, and highly specific measurement of glucose uptake in live cells—key for dissecting metabolic reprogramming in cancer and diabetes studies. Its fluorescence-based workflow, single-cell resolution, and built-in GLUT1 inhibition control set a new standard for reliable metabolic assays.

• Cy3 TSA Fluorescence System Kit: Amplifying Single-Cell Dete

  2026-06-19

  The Cy3 TSA Fluorescence System Kit revolutionizes signal amplification in immunohistochemistry and in situ hybridization, enabling ultrasensitive detection of low-abundance biomolecules in complex tissues. Leveraging tyramide signal amplification and Cy3 fluorophore chemistry, it empowers researchers to push the limits of spatial proteomics and single-cell analysis with robust, reproducible workflows.

• X-Gal for Blue-White Colony Screening: Optimized Workflows

  2026-06-19

  APExBIO's high-purity X-Gal empowers precise blue-white colony screening and β-galactosidase assays in recombinant DNA technology. This guide details advanced experimental workflows, troubleshooting strategies, and actionable insights derived from olfactory gene regulation research to help maximize assay sensitivity and reproducibility.

• GANT61 as a GLI Inhibitor: Advanced Workflows for Cancer Res

  2026-06-18

  GANT61 empowers researchers to dissect GLI-mediated transcription inhibition and overcome tumor immune evasion in cancer models. This article delivers actionable workflows, troubleshooting guidance, and strategic protocol enhancements to maximize the impact of GANT61 in translational studies.

• DRB and the Future of Cell Fate Control in Translational Res

  2026-06-18

  This article explores the mechanistic and translational frontiers of 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), spotlighting its strategic role in transcriptional regulation, cell fate transitions, and antiviral research. Drawing on recent breakthroughs in stem cell biology and RNA modification, we map the scientific rationale and actionable protocols for leveraging DRB, highlight its integration into contemporary workflows, and offer a critical outlook on its limitations and emerging opportunities.

• AI-10-49: Selective CBFβ-SMMHC Inhibitor for AML Research

  2026-06-17

  AI-10-49 is a potent, selective inhibitor of the leukemia-associated CBFβ-SMMHC fusion oncoprotein, central to acute myeloid leukemia research. It blocks the CBFβ-SMMHC and RUNX1 interaction with sub-micromolar potency, restoring RUNX1 function, inhibiting leukemia cell proliferation, and prolonging survival in preclinical models.

• Protease Inhibitor Cocktail: Precision Protein Protection in

  2026-06-17

  APExBIO’s Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) sets a new benchmark for protein degradation prevention, enabling high-fidelity workflows from Western blotting to co-immunoprecipitation. Its dual-component design empowers scientists to safeguard labile proteins even in the most protease-rich environments, bridging method rigor with translational opportunity.

• RIPA Lysis Buffer (Strong, without inhibitors): Technical Us

  2026-06-16

  RIPA Lysis Buffer (Strong, without inhibitors) enables robust lysis of animal cells and tissues for efficient protein extraction, particularly in workflows requiring customizable addition of protease and phosphatase inhibitors. It is not suitable for experiments where immediate inhibitor action is critical or where delayed sample processing may compromise protein integrity.

• Mitomycin C in Translational Oncology: Mechanisms and Pathwa

  2026-06-16

  Explore how Mitomycin C—an antitumor antibiotic—empowers translational researchers to dissect apoptosis signaling, overcome resistance, and design synergistic cancer therapies. This article delivers mechanistic insights, protocol best practices, and strategic guidance for integrating Mitomycin C into state-of-the-art experimental oncology, with a unique focus on bridging molecular rationale to clinical relevance and immunotherapy innovation.

• LL-37 and Mimetics: Distinct Biocidal and Antibiofilm Action

  2026-06-15

  The reference study dissects the biocidal and antibiofilm properties of the human host defense peptide LL-37 and its truncated mimetics, KE-18 and KR-12, against prominent pathogens. By deploying optimized crystal violet staining and XTT assays, the research clarifies that biocidal and antibiofilm effects are not always coupled, informing future peptide-based anti-infective strategies.

• Tivozanib (AV-951): Protocols and Pitfalls in VEGFR Inhibiti

  2026-06-15

  Tivozanib (AV-951) delivers unrivaled selectivity and potency for anti-angiogenic workflows in oncology research. This article details actionable experimental protocols, troubleshooting strategies, and advanced use-cases that leverage APExBIO’s Tivozanib for dissecting VEGFR signaling and optimizing renal cell carcinoma studies.

• CCG-1423: RhoA Inhibitor-Driven Workflows in Cancer Research

  2026-06-14

  CCG-1423 uniquely enables precise dissection of RhoA/ROCK signaling, facilitating advanced cancer and viral pathogenesis assays. Its selective mechanism and robust protocol adaptability set a new standard for translational research targeting cell proliferation, invasion, and apoptosis.

• Idoxuridine: Mechanistic Precision for Translational Antivir

  2026-06-13

  This thought-leadership article explores Idoxuridine's role as a mechanistically validated viral DNA synthesis inhibitor, offering actionable guidance for translational researchers. By bridging foundational antiviral mechanisms with strategic workflow design and referencing emerging pain research, we provide a perspective that advances beyond conventional product pages and supports innovation in viral and cellular pathophysiology research.

• Ciprofloxacin in Antimicrobial Resistance Research Workflows

  2026-06-12

  Harness Ciprofloxacin’s unique topoisomerase-inhibiting power for robust, reproducible antimicrobial resistance research. This guide details actionable workflows, advanced troubleshooting, and key insights from breakthrough studies to maximize experimental impact.

15101 records 1/1007 page Next 12345 下5页 Last page